SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Altheos, Inc., announced today the dosing of the first patient in a Phase 2a clinical trial of its lead investigational candidate, ATS907, a Rho kinase (ROCK)-selective inhibitor in development as a next-generation eye drop for the reduction of elevated intraocular pressure (IOP) in primary open angle glaucoma and ocular hypertension. ATS907 is one of a series of ROCK inhibitor compounds licensed from Asahi Kasei Pharma. Altheos also announced the company raised an additional $12.5M in its Series A financing, bringing the total to $32.5M. The round, which will be tranched as the company reaches specified milestones, was provided by existing investors Bay City Capital, Novo A/S, Canaan Partners, and additional investors.
